Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Filings indexed 749 across all filing types
Latest filing 2019-10-02 Board/Management Inform…
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
Director Change: Resignation of John Duncan
Board/Management Information Classification · 100% confidence The document is a company announcement dated 2 October 2019 regarding the resignation of a director, John Duncan. It specifically states the director's resignation and thanks him for his service. There is no financial data, no mention of reports or filings, and the content is focused solely on a change in the company's board of directors. This fits the definition of 'Board/Management Information' (MANG). The document length is short and focused on this announcement, confirming it is not a full report or other filing type.
2019-10-02 English
EXECUTIVE CHANGE: RESIGNATION OF CFO
Board/Management Information Classification · 95% confidence The document is a company announcement dated 19 September 2019 regarding the resignation of the Chief Financial Officer (CFO) of Pacific Edge Limited. It provides details about the executive change, including the resignation date and a statement from the CEO. The document does not contain any financial data, report content, or detailed analysis. It is a straightforward announcement about a management change. According to the filing definitions, announcements about changes in the company's board of directors or senior management fall under the category 'Board/Management Information' (Code: MANG). The document length is 4023 characters, which is relatively short and consistent with an announcement rather than a detailed report. Therefore, the appropriate classification is MANG with high confidence.
2019-09-18 English
D&O Ongoing Disclosures – Multiple
Regulatory Filings
2019-09-12 English
D&O Ongoing Disclosures – Multiple
Regulatory Filings
2019-08-22 English
Notice of Change in Issued Capital
Share Issue/Capital Change Classification · 95% confidence The document is a notice regarding the issuance of options to acquire ordinary shares, detailing the number of options issued, terms of issue, exercise price, and authority for the issue. It references Listing Rules and is focused on changes in issued capital related to employee incentive options. The document length is 4150 characters, which is relatively short and primarily an announcement of a capital change rather than a full financial report or detailed analysis. Therefore, it fits the category of a Share Issue/Capital Change announcement rather than a full Annual Report, Interim Report, or other financial filings.
2019-08-22 English
D&O Ongoing Disclosures – Multiple
Regulatory Filings
2019-08-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.